Catalyst Biosciences (CBIO) Stock Forecast, Price & News

Catalyst Biosciences' stock was trading at $0.5275 at the beginning of the year. Since then, CBIO stock has decreased by 56.4% and is now trading at $0.2301.
View the best growth stocks for 2023 here.

Catalyst Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 322,400 shares, an increase of 52.3% from the April 30th total of 211,700 shares. Based on an average trading volume of 901,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.3% of the shares of the company are sold short.
View Catalyst Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023.
View our CBIO earnings forecast.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.14. The biopharmaceutical company earned $2.30 million during the quarter, compared to the consensus estimate of $1 million.

Catalyst Biosciences declared a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be paid a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date of this dividend is Friday, January 13th.
Read our dividend analysis for CBIO.

Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Catalyst Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.32%), Acadian Asset Management LLC (0.69%) and Simplex Trading LLC (0.00%).
View institutional ownership trends.

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CBIO stock can currently be purchased for approximately $0.23.

Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $8.69 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.